Verrica Pharmaceuticals Announces FDA Approval of YCANTH(TM) (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Stock Information for Verrica Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.